These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 29346429

  • 1. The farnesoid X receptor agonist obeticholic acid upregulates biliary excretion of asymmetric dimethylarginine via MATE-1 during hepatic ischemia/reperfusion injury.
    Ferrigno A, Di Pasqua LG, Berardo C, Siciliano V, Rizzo V, Adorini L, Richelmi P, Vairetti M.
    PLoS One; 2018; 13(1):e0191430. PubMed ID: 29346429
    [Abstract] [Full Text] [Related]

  • 2. Changes in ADMA/DDAH pathway after hepatic ischemia/reperfusion injury in rats: the role of bile.
    Ferrigno A, Rizzo V, Bianchi A, Di Pasqua LG, Berardo C, Richelmi P, Vairetti M.
    Biomed Res Int; 2014; 2014():627434. PubMed ID: 25243167
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. MCD diet-induced steatohepatitis is associated with alterations in asymmetric dimethylarginine (ADMA) and its transporters.
    Di Pasqua LG, Berardo C, Rizzo V, Richelmi P, Croce AC, Vairetti M, Ferrigno A.
    Mol Cell Biochem; 2016 Aug; 419(1-2):147-55. PubMed ID: 27357826
    [Abstract] [Full Text] [Related]

  • 7. Age-related changes in ADMA-DDAH-NO pathway in rat liver subjected to partial ischemia followed by global reperfusion.
    Trocha M, Merwid-Ląd A, Chlebda-Sieragowska E, Szuba A, Pieśniewska M, Fereniec-Gołębiewska L, Kwiatkowska J, Szeląg A, Sozański T.
    Exp Gerontol; 2014 Feb; 50():45-51. PubMed ID: 24269305
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Role of asymmetric dimethylarginine in acute lung injury induced by cerebral ischemia/reperfusion injury in rats.
    Wu YH, Zhang X, Wang DH.
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Aug; 31(8):1289-94. PubMed ID: 21868307
    [Abstract] [Full Text] [Related]

  • 10. Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid.
    de Haan LR, Verheij J, van Golen RF, Horneffer-van der Sluis V, Lewis MR, Beuers UHW, van Gulik TM, Olde Damink SWM, Schaap FG, Heger M, Olthof PB.
    Biomolecules; 2021 Feb 10; 11(2):. PubMed ID: 33578971
    [Abstract] [Full Text] [Related]

  • 11. Coordinated regulation of dimethylarginine dimethylaminohydrolase-1 and cationic amino acid transporter-1 by farnesoid X receptor in mouse liver and kidney and its implication in the control of blood levels of asymmetric dimethylarginine.
    Li J, Wilson A, Gao X, Kuruba R, Liu Y, Poloyac S, Pitt B, Xie W, Li S.
    J Pharmacol Exp Ther; 2009 Oct 10; 331(1):234-43. PubMed ID: 19605523
    [Abstract] [Full Text] [Related]

  • 12. The impact of sitagliptin, inhibitor of dipeptidyl peptidase-4 (DPP-4), on the ADMA-DDAH-NO pathway in ischemic and reperfused rat livers.
    Trocha M, Nowak B, Merwid-Ląd A, Szuba A, Dzięgiel P, Pieśniewska M, Gomułkiewicz A, Wiśniewski J, Piasecki T, Gziut M, Szeląg A, Sozański T.
    Adv Clin Exp Med; 2018 Nov 10; 27(11):1483-1490. PubMed ID: 30303311
    [Abstract] [Full Text] [Related]

  • 13. Liver plays a central role in asymmetric dimethylarginine-mediated organ injury.
    Ferrigno A, Di Pasqua LG, Berardo C, Richelmi P, Vairetti M.
    World J Gastroenterol; 2015 May 07; 21(17):5131-7. PubMed ID: 25954086
    [Abstract] [Full Text] [Related]

  • 14. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease.
    Matsuguma K, Ueda S, Yamagishi S, Matsumoto Y, Kaneyuki U, Shibata R, Fujimura T, Matsuoka H, Kimoto M, Kato S, Imaizumi T, Okuda S.
    J Am Soc Nephrol; 2006 Aug 07; 17(8):2176-83. PubMed ID: 16807406
    [Abstract] [Full Text] [Related]

  • 15. Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis.
    Carino A, Biagioli M, Marchianò S, Fiorucci C, Bordoni M, Roselli R, Di Giorgio C, Baldoni M, Ricci P, Monti MC, Morretta E, Zampella A, Distrutti E, Fiorucci S.
    Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Sep 07; 1865(9):158733. PubMed ID: 32371093
    [Abstract] [Full Text] [Related]

  • 16. Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in Rats.
    Ceulemans LJ, Verbeke L, Decuypere JP, Farré R, De Hertogh G, Lenaerts K, Jochmans I, Monbaliu D, Nevens F, Tack J, Laleman W, Pirenne J.
    PLoS One; 2017 Sep 07; 12(1):e0169331. PubMed ID: 28060943
    [Abstract] [Full Text] [Related]

  • 17. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.
    Singh AB, Dong B, Kraemer FB, Xu Y, Zhang Y, Liu J.
    Arterioscler Thromb Vasc Biol; 2018 Oct 07; 38(10):2448-2459. PubMed ID: 30354208
    [Abstract] [Full Text] [Related]

  • 18. Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension.
    Mookerjee RP, Mehta G, Balasubramaniyan V, Mohamed Fel Z, Davies N, Sharma V, Iwakiri Y, Jalan R.
    J Hepatol; 2015 Feb 07; 62(2):325-31. PubMed ID: 25152204
    [Abstract] [Full Text] [Related]

  • 19. Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation.
    Hu T, Chouinard M, Cox AL, Sipes P, Marcelo M, Ficorilli J, Li S, Gao H, Ryan TP, Michael MD, Michael LF.
    J Biol Chem; 2006 Dec 29; 281(52):39831-8. PubMed ID: 17065154
    [Abstract] [Full Text] [Related]

  • 20. Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms.
    Guo C, LaCerte C, Edwards JE, Brouwer KR, Brouwer KLR.
    J Pharmacol Exp Ther; 2018 May 29; 365(2):413-421. PubMed ID: 29487110
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.